8-K: Sutro Biopharma Announces Positive Topline Results from Luveltamab Tazevibulin Trial in Ovarian Cancer

Sutro Biopharma reports a 32% objective response rate and 96% disease control rate in the dose-optimization phase of its luveltamab tazevibulin trial for platinum-resistant ovarian cancer.

Summary

• Sutro Biopharma has announced topline results from the dose-optimization portion (Part 1) of the REFRME-O1 trial for luveltamab tazevibulin (luvelta) in platinum-resistant ovarian cancer (PROC).
• The trial evaluated luvelta in patients with low, medium, and high folate receptor (FR) expression levels, including those with at least 25% Tumor Proportion Score (TPS).
• Patients were randomized to either a 5.2 mg/kg dose with prophylactic pegfilgrastim for two cycles followed by 4.3 mg/kg for subsequent cycles, or a 4.3 mg/kg dose for all cycles.
• The 5.2 mg/kg group (N=25) achieved a 32% objective response rate, including one partial response confirmed post data extraction as of August 16, 2024.
• The disease control rate in the 5.2 mg/kg group was 96%.
• Approximately half of the patients treated were ineligible for an approved FR-targeting antibody drug conjugate (ADC).
• 88% of patients had previously received bevacizumab.
• Grade 3 or higher neutropenia occurred in 32% of patients, but there was no febrile neutropenia.
• REFRME-O1 (Part 2) is an ongoing global registrational trial evaluating the 5.2 mg/kg dose followed by 4.3 mg/kg in approximately 500 patients randomized 1:1 to luvelta or investigator's choice of chemotherapy.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial results with a high objective response rate and disease control rate, suggesting a promising outlook for the drug. However, there are risks associated with ongoing trials and regulatory approvals, which temper the overall sentiment.

Positives

• The 32% objective response rate is a promising result for luvelta in treating platinum-resistant ovarian cancer.
• The high disease control rate of 96% suggests that luvelta is effective in stabilizing the disease.
• The fact that half of the patients were ineligible for other FR-targeting ADCs indicates a potential for luvelta to address an unmet need.
• The absence of febrile neutropenia is a positive safety signal.

Negatives

• Grade 3 or higher neutropenia occurred in 32% of patients, indicating a potential side effect that needs to be managed.

Risks

• The trial is still ongoing, and the results of Part 2 may differ from Part 1.
• The development and regulatory approval of luvelta are subject to risks and uncertainties.
• The market size for luvelta may be smaller than anticipated.
• There are risks related to clinical trial sites, supply chain, and manufacturing facilities.
• The company's ability to fund development activities and achieve development goals is a risk.

Future Outlook

The company is continuing the REFRME-O1 Part 2 registrational trial, which will enroll approximately 500 patients. The company anticipates further clinical development activities, regulatory filings, and potential business development and partnering transactions.

Industry Context

The announcement is significant in the context of the ongoing development of targeted therapies for ovarian cancer, particularly for patients who have become resistant to platinum-based chemotherapy. The results suggest that luvelta could be a valuable addition to the treatment landscape, especially for patients who are ineligible for existing FR-targeting ADCs.

Comparison to Industry Standards

• The 32% objective response rate for luvelta is competitive with other antibody-drug conjugates in development for ovarian cancer.
• Mirvetuximab soravtansine, another FR-targeting ADC, has shown similar response rates in clinical trials for platinum-resistant ovarian cancer.
• The 96% disease control rate is also a positive indicator, suggesting that luvelta is effective in stabilizing the disease, which is a key goal in treating advanced cancers.
• The safety profile, with 32% grade 3 or higher neutropenia but no febrile neutropenia, is within the range of what is typically observed with ADCs.

Stakeholder Impact

• Shareholders may react positively to the promising clinical trial results.
• Patients with platinum-resistant ovarian cancer may benefit from a new treatment option.
• Employees of Sutro Biopharma may be encouraged by the progress of the company's pipeline.
• Potential partners may be more interested in collaborating with Sutro Biopharma.

Next Steps

• The company will continue enrollment in the REFRME-O1 Part 2 registrational trial.
• The company will continue to analyze the data from the trial.
• The company will pursue regulatory approvals for luvelta.

Key Dates

Keywords

luveltamab tazevibulin, ovarian cancer, platinum-resistant, antibody drug conjugate, ADC, folate receptor, clinical trial, REFRME-O1, objective response rate, disease control rate, neutropenia